Immunome Ownership | Who Owns Immunome?

Overview Forecast RevenueFinancials Chart

Immunome Ownership Summary

Immunome is owned by 49.36% institutional investors, 7.85% insiders, and 42.79% retail investors. Blackrock is the largest institutional shareholder, holding 36.46% of IMNM shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 5.47% of its assets in Immunome shares.

IMNM Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Immunome	49.36%	7.85%	42.79%
Sector	Healthcare Stocks	232.64%	10.66%	-143.30%
Industry	Biotech Stocks	382.13%	10.41%	-292.54%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock	3.76M	36.46%	$45.48M
Fmr	13.06M	15.01%	$152.89M
T. rowe price investment management	8.42M	9.67%	$98.58M
Blackrock funding, inc. /de	7.59M	8.63%	$163.14M
Vanguard group	6.04M	6.87%	$129.71M
Redmile group	5.02M	5.77%	$58.82M
Janus henderson group	3.46M	5.74%	$36.73M
Point72 asset management	4.82M	5.54%	$56.49M
Enavate sciences gp	4.77M	5.48%	$55.84M
Primecap management co/ca/	4.69M	5.33%	$100.64M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Enavate sciences gp	4.77M	17.05%	$55.84M
Redmile group	5.02M	5.72%	$58.82M
Opaleye management	3.19M	5.27%	$37.30M
Pivotal bioventure partners investment advisor	502.51K	3.40%	$5.88M
Silverarc capital management	1.13M	3.36%	$24.19M
Monashee investment management	274.86K	3.33%	$5.90M
Ecor1 capital	4.08M	2.29%	$47.77M
Nan fung trinity (hk)	714.55K	1.22%	$15.35M
Birchview capital, lp	105.00K	0.93%	$1.23M
Readystate asset management lp	1.32M	0.66%	$15.44M

Top Buyers

Holder	Shares	% Assets	Change
Fmr	13.06M	0.01%	6.89M
Blackrock	3.76M	0.00%	2.93M
Jpmorgan chase	2.86M	0.00%	2.82M
Blackrock funding, inc. /de	7.59M	0.00%	1.77M
Primecap management co/ca/	4.69M	0.08%	1.67M

Top Sellers

Holder	Shares	% Assets	Change
Toronto dominion bank	1.04M	0.02%	-1.05M
Vestal point capital, lp	-	-	-1.00M
Avidity partners management lp	-	-	-873.89K
Brown advisory	-	-	-860.78K
Adage capital partners gp	-	-	-775.00K

New Positions

Holder	Shares	% Assets	Change	Value
Silverarc capital management	1.13M	3.36%	1.13M	$24.19M
Pivotal bioventure partners investment advisor	502.51K	3.40%	502.51K	$5.88M
Parkman healthcare partners	351.13K	0.43%	351.13K	$4.11M
Monashee investment management	274.86K	3.33%	274.86K	$5.90M
Axa investment managers	180.06K	0.01%	180.06K	$2.11M

Sold Out

Holder	Change
National bank of canada /fi/	-1.00
Massmutual trust co fsb/adv	-5.00
Eversource wealth advisors	-8.00
Us bancorp \de\	-21.00
Lindbrook capital	-38.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	109	-33.54%	43,416,568	-52.49%	49	0.45%	67	-27.96%	23	-37.84%
Sep 30, 2025	160	8.11%	91,368,868	15.03%	105	1.26%	91	7.06%	37	-
Jun 30, 2025	148	0.68%	79,432,018	9.01%	91	1.08%	85	-20.56%	37	105.56%
Mar 31, 2025	147	18.55%	76,924,342	44.29%	96	1.24%	108	54.29%	17	-51.43%
Dec 31, 2024	123	1.65%	53,309,287	3.16%	88	1.20%	69	4.55%	35	25.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Fidelity Growth Compy Commingled Pl S	6.19M	5.47%	-
T. Rowe Price US Small-Cap Core Equity	5.13M	4.65%	2.01M
T. Rowe Price Small-Cap Stock	5.25M	4.64%	119.97K
Fidelity Growth Company Fund	4.51M	3.98%	-
PRIMECAP Odyssey Aggressive Growth	3.81M	3.46%	1.14M
Fidelity Growth Compy Commingled Pl O	1.79M	2.97%	-
Vanguard Total Stock Mkt Idx Inv	3.14M	2.78%	7.82K
State Street® SPDR® S&P® Biotech ETF	2.93M	2.59%	44.17K
T. Rowe Price Instl Small-Cap Stock	2.84M	2.51%	65.14K
iShares Russell 2000 ETF	2.47M	2.18%	-20.16K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Apr 02, 2026	Higgins Jack	Chief Scientific Officer	Sell	$204.24K
Apr 02, 2026	Rosett Max	Chief Financial Officer	Sell	$1.39M
Apr 02, 2026	Rosett Max	Chief Financial Officer	Sell	$30.21K
Mar 27, 2026	SIEGALL CLAY B	President and CEO	Buy	$500.60K
Mar 23, 2026	WAGENHEIM PHILIP	-	Sell	$582.33K

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	-	3
2026 Q1	3	2
2025 Q4	4	2
2025 Q3	-	-
2025 Q2	1	-

IMNM Ownership FAQ

Who Owns Immunome?

Immunome shareholders are primarily institutional investors at 49.36%, followed by 7.85% insiders and 42.79% retail investors. The average institutional ownership in Immunome's industry, Biotech Stocks , is 382.13%, which Immunome falls below.

Who owns the most shares of Immunome?

Immunome’s largest shareholders are Blackrock (3.76M shares, 36.46%), Fmr (13.06M shares, 15.01%), and T. rowe price investment management (8.42M shares, 9.67%). Together, they hold 61.14% of Immunome’s total shares outstanding.

Does Blackrock own Immunome?

Yes, BlackRock owns 36.46% of Immunome, totaling 3.76M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 45.48M$. In the last quarter, BlackRock increased its holdings by 2.93M shares, a 353.41% change.

Who is Immunome’s biggest shareholder by percentage of total assets invested?

Enavate sciences gp is Immunome’s biggest shareholder by percentage of total assets invested, with 17.05% of its assets in 4.77M Immunome shares, valued at 55.84M$.

Who is the top mutual fund holder of Immunome shares?

Fidelity Growth Compy Commingled Pl S is the top mutual fund holder of Immunome shares, with 5.47% of its total shares outstanding invested in 6.19M Immunome shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools